Carbamate Parenteral Formulation via Cyclodextrin Inclusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current parenteral liquid formulations for carbamate compounds used in treating epilepsy often contain benzyl alcohol and surfactants, which cause side effects and have limited solubility and storage stability issues, making them unsuitable for emergency administration.
Innovation Solution
A parenteral liquid formulation incorporating a cyclodextrin derivative, such as hydroxyalkyl-cyclodextrin or sulfoalkyl ether-cyclodextrin, to enhance the solubility and storage stability of carbamate compounds without using benzyl alcohol or toxic surfactants, allowing for immediate and effective administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If benzyl alcohol and surfactants are used to improve solubility of carbamate compounds in parenteral formulations, then the solubility is improved, but unwanted side effects occur and safety is compromised
Solution Approach 1:
The patent introduces cyclodextrin derivatives as intermediary substances that form inclusion complexes with carbamate compounds. These cyclodextrin derivatives act as mediators between the hydrophobic carbamate compound and the aqueous formulation medium, enabling solubility enhancement without requiring harmful benzyl alcohol or surfactants. The cyclodextrin derivative binds to the carbamate compound within its cavity structure, creating a water-soluble complex that can be administered safely.
Solution Approach 2:
The patent changes the chemical parameters of the formulation by replacing traditional solubilizing agents (benzyl alcohol, surfactants) with cyclodextrin derivatives that have different molecular structures and interaction mechanisms. This parameter change allows the formulation to achieve high solubility through inclusion complex formation rather than through the harmful mechanisms of the previous agents.
2Quantity of substance
If benzyl alcohol is used at high concentrations to achieve adequate solubility, then the solubility is improved, but precipitation occurs during long-term storage
Solution Approach 1:
The cyclodextrin derivative serves as a stable intermediary that forms a protected inclusion complex with the carbamate compound. This complex structure prevents the carbamate from precipitating during storage because the cyclodextrin cavity continuously holds the drug molecule in a soluble, stabilized state. The intermediary structure eliminates the precipitation problem that occurs with high-concentration benzyl alcohol formulations.
3Adaptability or versatility
If oral formulations are used for epilepsy treatment, then repeated administration can be maintained, but emergency treatment is not possible when patients cannot take medication orally
Solution Approach 1:
The patent creates a universal parenteral formulation that can be administered through multiple routes (intravenous, intramuscular, subcutaneous) to address both emergency and chronic treatment needs. The cyclodextrin derivative-based formulation maintains high solubility and stability across different administration routes, making it universally applicable for both emergency rescue and long-term epilepsy management, eliminating the limitation of oral-only administration.
4Quantity of substance
If cyclodextrin derivatives are used to increase solubility, then the solubility and storage stability are improved, but the formulation complexity increases
Solution Approach 1:
The cyclodextrin derivative is a single-component intermediary substance that simplifies the formulation approach compared to using multiple traditional solubilizing agents (benzyl alcohol, surfactants, emulsifiers). By employing one type of molecule with a well-defined inclusion complex mechanism, the patent reduces formulation complexity while achieving superior solubility and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation significantly increases the solubility of carbamate compounds in aqueous solutions, reduces the required dose volume, and provides high storage stability, enabling rapid and safe administration without causing side effects, particularly in emergency situations.
Implementation Method 1
Cyclodextrins can stabilize a drug by reversibly forming a water-soluble complex with the drug
Data Source
AI summary
The present invention relates to a parenteral liquid preparation containing, as active ingredients; a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof; and a cyclodextrin derivative.